



Synthesis, Spectral Properties and Anti-tumor Evaluations of Some Novel 2-substituted-1,3-Thiazole Derivatives

Asmaa S. Salman^{1*}

¹Department of Chemistry, Faculty of Science, Al-Azhar University, Girls' Branch, Nasr City, Cairo, Egypt.

Author's contribution

The sole author designed, analyzed and interpreted and prepared the manuscript.

Article Information

DOI: 10.9734/ACSJ/2016/26694

Editor(s):

(1) Anonymous.

Reviewers:

(1) Nitulescu George Mihai, University of Medicine and Pharmacy, Romania.

(2) F. M. A. El-Taweel, University of Damietta, Egypt.

(3) Nadeem Siddiqui, Hamdard University, New Delhi, India.

(4) Awatef Mohamed Elmaghraby, South Valley University, Egypt.

Complete Peer review History: <http://sciencedomain.org/review-history/15351>

Original Research Article

Received 29th April 2016

Accepted 29th June 2016

Published 9th July 2016

ABSTRACT

Reaction of N^2 -(4-chlorophenyl)-1,3-thiazole-2,4-diamine 1 with ammonium thiocyanate, phenyl isothiocyanate, acetic anhydride, phenacyl bromide, 2-chloro- N -(4-chlorophenyl) acetamide and acetic anhydride / cyanoacetic acid afforded the corresponding N -[4-(4-chlorophenyl)amino-1,3-thiazol-2-yl]thiourea 2, N -[4-(4-chlorophenyl)amino-1,3-thiazol-2-yl]- N -phenylthiourea 3, N -acetyl- N -[4-(4-chlorophenyl)amino-1,3-thiazol-2-yl]acetamide 7, 2-(1,3-thiazol-2-ylamino)-1-phenylethanone derivative 8, 2-(1,3-thiazol-2-ylamino)- N -(4-chlorophenyl)acetamide derivative 9 and N -(1,3-thiazol-2-yl)-2-cyanoacetamide derivative 11. Reaction 1 with phenyl isothiocyanate in basic DMF yielded the intermediate potassium salt 14, then treatment of intermediate 14 with α -halocarbonyl compounds such as ethyl chloroacetate and/ or 2-chloro- N -(4-chlorophenyl) acetamide afforded ethyl { N -(1,3-thiazol-2-yl)- N -phenyl-carbamimidoyl}thio}acetate 15 and 2-[(4-chlorophenyl)amino]-2-oxoethyl N -(1,3-thiazol-2-yl)- N -phenyl-imidothiocarbamate 16 respectively. Reaction 1 with 1 H -pyrazole-4-carboxaldehyde 17 or 1 H -indole-3-carboxaldehyde 18 afforded N^2 -[(1 H -pyrazol-4-yl) methylene]-1,3-thiazole-2,4-diamine 19 and N^2 -[(1 H -indol-3-yl)methylene]-1,3-

*Corresponding author: E-mail: salman_2007_ok@yahoo.com;

thiazol-2,4-diamine 20 respectively. Structures of the newly synthesized compounds have been confirmed by elemental analysis and spectra data. Some of the newly synthesized compounds were screened *in vitro* for their anti-tumor activities against human cancer cell line MCF-7.

Keywords: 1,3-thiazole-2,4-diamine; thiourea; carbamimidothioate; pyrazole; anti-tumor activities.

1. INTRODUCTION

The main objectives of medicinal chemistry are the design and synthesis, compounds having value as human therapeutic agents. In recent years, cancer is the biggest health issue in the world. Cancer disease which the control of cell growth and nuclear proliferation lost in one or more cells and end leading either to the tumor such as breast, prostate cancer, and therapeutic options include surgery, chemotherapy, and radiotherapy. The major goal of cancer treatment is to attain maximum therapeutic damage of tumor cells in a collection with the minimum concentration of the drug. This can be carried out by selective antitumor preparation, the cytostatic effects of which would be restricted within tumor tissue [1]. The find of new chemical structures that can act as more effective anticancer agents is still the main challenge hard to medicinal chemists. The important advances achieved over recent decades in the research and development of multiple anticancer drugs, existing anticancer drugs still have main limitations such as drug resistance, lack of selectivity and unwanted side effects. Thus, there is a strong request for the find and development of effective new cancer treatment devoid side effects [2-4].

In recent years development antitumor chemical drugs which including the heterocyclic ring which has interesting biological activities [5,6].Thiazole is five-membered heterocyclic ring have many biologically active Also, 2-amino-thiazoles offer a wide range of biological potencies including antimicrobial [7], antiviral [8], anti-inflammatory activities [9], anti-Alzheimer [10], anti-tubercular activity [11], anti-convulsant activity [12], anti-HIV-1 [13]. Antitumor activity of thiazole was easily based via being incorporated into a variety of therapeutically active agents like bleomycin [14], epothilones [15] and dasatinib [16,17].From literature survey, it was found that aminothiazole proved to have a broad spectrum of activity against most of the tested tumor cell lines [18-21].

On the way of continuing our work on the synthesis of new heterocyclic compounds with expected biological activities, we report herein the synthesis of some new 1,3-thiazole-2,4-diamine derivatives and their characterization by

IR, NMR and Mass spectrometry techniques. Some synthesized compounds were also screened for their anti-tumor evaluation against the breast cancer cell line (MCF-7).

2. MATERIALS AND METHODS

2.1 General Conditions

Melting points were measured on a Gallenkamp apparatus and are uncorrected. IR spectra were measured using KBr discs on Pye Unicam SP-1000 spectrophotometer. The ¹H-NMR and ¹³C NMR spectra were determined in DMSO-d₆ at 400 MHz on a Varian Mercury VX 300 NMR spectrometer using TMS as an internal standard. Mass spectra were measured on a GCMS-QP1000 EX spectrometer at 70 Ev. Elemental analyses were carried out at the Microanalytical center of Cairo University and the main chemical warfare laboratories. *N*⁴-(4-chlorophenyl)-1,3-thiazole-2,4-diamine **1** was prepared according to previously reported procedure [22].

2.2 Synthesis

2.2.1 *N*-[4-(4-Chlorophenyl)amino-1,3-thiazol-2-yl]thiourea **2**

To *N*⁴-(4-chlorophenyl)-1,3-thiazole-2,4-diamine **1** (0.01 mol), concentrated hydrochloric acid (0.01mol) was added and the solution was warmed. A saturated solution of ammonium thiocyanate in water (5 gm in 3 mL) was added slowly in above solution. The mixture was reflux for 45 min. The reaction mixture was poured in cold water. The solid obtained was filtered off and recrystallized from ethanol to give **2** as yellow powder. Yield: 70 %. m.p.: 140-142°C. IR (KBr): ν/cm^{-1} : 3340, 3269, 3250, 3200 (NH₂, 2 NH), 3066, 2931 (CH), 1240 (C=S), 1608 (C=N). ¹H-NMR (DMSO-d₆) δ ppm: 4.27 (s, 2H, NH₂ exchanged by D₂O), 7.03 (s, 1H, C₅-H thiazole), 7.30-7.57 (m, 4H, Ar-H), 10.12 (s, 1H, NH exchanged by D₂O), 10.50 (s, 1H, NH exchanged by D₂O). MS *m/z* (%): 285 (M⁺, 21.3), 269 (4.6), 113 (10.5), 111(28), 60 (6.1), 57 (100). Anal. Calcd. for C₁₀H₉ClN₄S₂ (284.79) : C, 42.17 ; H, 3.19 ; Cl, 12.45 ; N, 19.67 ; S, 22.52. Found: C, 42.07; H, 3.09 ; Cl, 12.25 ; N, 19.47 ; S, 22.32.

2.2.2 N-[4-(4-Chlorophenyl)amino-1,3-thiazol-2-yl]-N'-phenylthiourea 3

A mixture of *N*⁴-(4-chlorophenyl)-1,3-thiazole-2,4-diamine **1** (0.01 mol) and phenyl isothiocyanate (0.01 mol) in 1,4-dioxane (40 mL) was refluxed in the presence of few drops of triethylamine (TEA) for 8h. The solid product separated from the hot mixture was filtered off, washed with water and recrystallized from pot. ether to give **3** as yellow powder. Yield: 55%. m.p.: 60 - 62°C. IR (KBr): ν/cm^{-1} : 3217, 3186, 3116 (3 NH), 3005, 2995, 2935 (CH), 1250 (C=S), 1597 (C=N). ¹H-NMR (DMSO-d₆) δ ppm: 7.11 (s, 1H, C₅-H thiazole), 7.29 - 7.61 (m, 9H, Ar-H), 10.02 (s, 1H, NH exchanged by D₂O), 11.03 (s, 1H, NH exchanged by D₂O). MS *m/z* (%): 361 (M⁺, 1.1), 325 (3.8), 264 (9.3), 230 (26.5), 224 (7.2), 113 (26.4), 55 (100). Anal. Calcd. for C₁₆H₁₃ClN₄S₂ (360.88): C, 53.25; H, 3.63; Cl, 9.82; N, 15.52; S, 17.77. Found: C, 53.05; H, 3.43; Cl, 9.62; N, 15.32; S, 17.57.

2.2.3 3-[4-(4-Chlorophenyl)amino-1,3-thiazol-2-yl]-6-(4-methoxyphenyl)-4-oxo-1-phenyl-2-thioxo-1,2,3,4-tetrahydro-pyrimidine-5-carbonitrile 4

A mixture of thiourea derivative **3** (0.01 mol), ethyl cyanoacetate (0.01 mol) and anisaldehyde (0.01 mol) in ethanol 30 mL was added few drops of TEA. The reaction mixture was refluxed for 6h. The solid product separated from the hot mixture was filtered off, washed with water and recrystallized from ethanol to give **4** as a yellow plate. Yield: 80%. m.p.: 309 - 310°. IR (KBr): ν/cm^{-1} : 3275 (NH), 3027.2904, 2839 (CH), 2214 (CN), 1670 (C=O), 1246 (C=S). ¹H-NMR (DMSO-d₆) δ ppm: 3.25 (s, 3H, OCH₃), 7.04 (s, 1H, C₅-H thiazole), 7.14 - 8.04 (m, 13H, Ar-H), 8.27 (s, 1H, NH exchanged by D₂O). ¹³C NMR (DMSO-d₆) δ ppm: 62.52 (OCH₃), 115.26, 115.43, 116.63 (CN), 124.41, 129.84, 132.13, 133.97, 154.91 (C-N), 162.81 (C-O), 164 (C=O), 180 (C-S), 186 (C=S). Anal. Calcd. for C₂₇H₁₈ClN₅O₂S₂ (544.04): C, 59.61; H, 3.33; Cl, 6.52; N, 12.87; S, 11.79. Found: C, 59.41; H, 3.13; Cl, 6.32; N, 12.67; S, 11.69.

2.2.4 6-(4-Aminophenyl)-1-[4-(4-chlorophenyl)amino-1,3-thiazol-2-yl]-4-(4-chlorophenyl)-3-phenyl-3,4-dihydropyrimidine-2(1H)-thione 5

A mixture of 1-(4-aminophenyl)-3-(4-chlorophenyl) prop-2-en-1-one **5** (0.01 mol) and

thiourea derivative **3** (0.01 mol) in ethanol (50 mL) and sodium hydroxide (0.01 mol) dissolved in minimum quantity of water was refluxed 6h. The reaction mixture was allowed to cooled and then acidified with dilute hydrochloric acid. The solid obtained was collected by filtration, washed with water, and recrystallized from ethanol to give **6** as a yellow granule. Yield: 75%. m.p.: 260-261°C. IR (KBr): ν/cm^{-1} : 3217, 3166, 3116 (NH₂, NH), 3035, 2985, 2936 (CH), 1254 (C=S). ¹H-NMR (DMSO-d₆) δ ppm: 4.48 (d, 1H, C₄-H pyrimidine), 6.60 (d, 1H, C₅-H pyrimidine), 5.02 (s, 2H, NH₂, exchanged by D₂O-), 7.11-7.81 (m, 18 H, Ar-H and C₅-H thiazole), 8.91 (s, 1H, NH, exchanged by D₂O). Anal. Calcd. for C₃₁H₂₃Cl₂N₅S₂ (600.58): C, 61.99; H, 3.86; Cl, 11.81; N, 11.66; S, 10.68. Found: C, 61.69; H, 3.66; Cl, 11.61; N, 11.46; S, 10.48.

2.2.5 N-Acetyl-N-[4-(4-chlorophenyl)amino-1,3-thiazol-2-yl]acetamide 7

A mixture of *N*⁴-(4-chlorophenyl)-1,3-thiazole-2,4-diamine **1** (0.01 mol) and acetic anhydride (5 mL) was heated under reflux for 5h. Then, the reaction mixture was cooled and poured into ice. The solid product was filtered off, washed with water, dried and recrystallized from ethanol / DMF (2 :1) to give compound **7** as a brown powder. Yield: 70%. m.p.: 162-164°C. IR (KBr): ν/cm^{-1} : 3136 (NH), 3055, 2981, 2877 (CH), 1670 (C=O). ¹H-NMR (DMSO-d₆) δ ppm: 2.70 (s, 3H, CH₃), 2.86 (s, 3H, CH₃), 6.83 (s, 1H, C₅-H thiazole), 7.48-7.61 (m, 4H, Ar-H), 8.91 (s, 1H, NH exchanged by D₂O). ¹³C NMR (DMSO-d₆) δ ppm: 21.09, 24.09 (2CH₃), 130.34, 131.49, 134.24, 138.83, 149.21, 157.82 (C-N), 168.42, 170.44 (2 C=O), 179 (C-S). Anal. Calcd. for C₁₃H₁₂ClN₃O₂S (309.77): C, 50.40; H, 3.90; Cl, 11.44; N, 13.56; S, 10.35. Found: C, 50.20; H, 3.60; Cl, 11.24; N, 13.36; S, 10.25.

2.2.6 2-[4-(4-Chlorophenyl)amino-1,3-thiazol-2-ylamino]-1-phenylethanone 8

To a mixture of *N*⁴-(4-chlorophenyl)-1,3-thiazole-2,4-diamine **1** (0.01 mol) and phenacyl bromide (0.01 mol) in ethanol (30 mL) was added few drops of TEA. The reaction mixture was refluxed for 6h. The solid product separated after cool was filtered off, washed with water and recrystallized from ethanol to give **8** as brown plates. Yield: 70%. m.p.: 100-102°C. IR (KBr): ν/cm^{-1} : 3186, 3147 (2 NH), 3059, 2924, 2850 (CH), 1685 (C=O). ¹H-NMR (DMSO-d₆) δ ppm: 4.21 (s, 2H, CH₂), 6.84 (s, 1H, C₅-H thiazole), 7.15-7.99 (m, 9H, Ar-H), 8.07 (s, 1H, NH exchanged by D₂O),

11.08 (s, 1H, NH exchanged by D₂O) . MS *m/z* (%): 344 (M⁺, 15), 316 (12.5), 270 (28.9), 232 (3.8), 113 (4.3), 105 (100), 77(41.6). Anal. Calcd. for C₁₇H₁₄Cl N₃O S (343.83): C, 59.38; H, 4.10; Cl, 10.31; N, 12.22; S, 9.33. Found : C, 59.18; H, 4.00 ; Cl, 10.11; N, 12.02; S, 9.23.

2.2.7 2-(4-(4-Chlorophenyl)amino-1,3-thiazol-2-ylamino)-N-(4-chlorophenyl)acetamide 9

To a mixture of *N*⁴-(4-chlorophenyl)-1,3-thiazole-2,4-diamine **1** (0.01 mol) and 2-chloro-*N*-(4-chlorophenyl) acetamide (0.01 mol) in ethanol (30 mL) was added few drops of TEA. The reaction mixture was refluxed for 6h. The solid product separated after cool was filtered off, washed with water and recrystallized from ethanol to give **9** as a white plat .Yield: 80 % .m.p.:145-147°C. IR (KBr): *u/cm*⁻¹: 3271 , 3197 , 3128 (3 NH) , 3082 , 2974 , 2931, 2893 (CH), 1678 (C=O) .¹H-NMR (DMSO-*d*₆) δ ppm: 4.22 (s, 2H , CH₂) , 6.85 (s, 1H, C₅-H thiazole), 7.30 - 7.64 (m, 8 H, Ar-H), 8.27 (s, 1H, NH exchanged by D₂O) ,10.36 (s, 1H, NH exchanged by D₂O) , 10.93 (s, 1H, NH, exchanged by D₂O).¹³C NMR (DMSO-*d*₆) δ ppm: 33.18 (CH₂) ,121.08, 123.21, 127.50, 128.87, 129.20 ,130.24, 134.45, 137.97, 138.01, 140.72, 147,02, 156.28 (C-N), 164.36 (C=O), 184.01 (C-S). Anal. Calcd. For C₁₇H₁₄Cl₂N₄OS(393.29) : C, 51.92; H, 3.59; Cl ,18.03; N,14.25; S, 8.15. Found: C, 51.62; H, 3.39; Cl, 18.00; N, 14.05; S, 8.00.

2.2.8 4-(4-Chlorophenyl)amino-1-[4-(4-chlorophenyl)amino-1,3-thiazol-2-yl]-1H-imidazole-2(3H)-thione 10

A mixture of acetamide derivative **9** (0.01mol) and ammonium thiocyanate (0.015 mol) in glacial acetic acid (20 mL) was refluxed for 6h. After cooling, the separated solid was filtered off and recrystallized from ethanol to give **10** as brown plates. Yield: 60 % .m.p.:170-172°C. IR (KBr): *u/cm*⁻¹: 3302, 3263, 3190 (3 NH), 3066, 2927(CH), 1261(C=S).¹H-NMR (DMSO-*d*₆) δ ppm: 7.29 (s , 1H, C₅-H thiazole), 7.35 (s,1H , C₄-H imidazole), 7.40 -7.71 (m, 8 H, Ar-H), 8.61 (s, 1H, NH exchanged by D₂O),10.02(s,1H, NH , exchanged by D₂O),11.21(s ,1H , NH exchanged by D₂O).¹³C NMR (DMSO-*d*₆) δ ppm: 120.12, 120.89, 126.90, 127.14, 127.56, 129.09, 129.19, 129.22, 137.59, 138.71 , 155.12 (C-N) , 170.70 (C-S),186 (C=S).Anal. Calcd. for C₁₈H₁₃Cl₂N₅S₂(434.36): C , 49.77 ; H, 3.02 ; Cl, 16.32 ; N ,16.12 ; S, 14.76. Found: C, 49.57; H, 3.00; Cl, 16.12; N, 16.02; S, 14.46.

2.2.9 N-[4-(4-Chlorophenyl)amino-1,3-thiazol-2-yl]-2-cyanoacetamide 11

A solution of cyanoacetic acid (0.05 mo l) in acetic anhydride (15 mL) was heated under reflux over water bath for 5 minutes , then compounds **1** (0.05 mol) was added and the reaction mixture was heated for further 1h. at 60-70°C. The reaction mixture was cooled, and the precipitate was filtered off and recrystallized from ethanol to give **11** as a brown powder. Yield: 60%. m.p.: 141-143°C. IR (KBr): *u/cm*⁻¹: 3136, 3100 (2 NH) , 3006, 2931 (CH) , 2200 (CN), 1670 (C=O) .¹H-NMR (DMSO-*d*₆) δ ppm: 4.02 (s, 2H, CH₂) , 6.83 (s,1H , C₅- H thiazole) , 7.48 -7.61(m, 4 H, Ar-H), 10.22 (s, 1H , NH exchanged by D₂O),11.01(s ,1H , NH exchanged by D₂O).293 (M⁺, 90.7),294 (M⁺+1, 19.8), 258 (4.9), 232 (4.9), 218 (11.5) , 190 (7.5),181 (16.5), 153 (100), 113 (43.4),77(27.2). Anal. Calcd. for C₁₂H₉Cl N₄OS (292.74): C,49.23 ; H , 3.10; Cl , 12.11 ; N, 19.14; S ,10.95. Found: C,49.03 ; H 3.00; Cl , 12.01 ; N, 19.04 ; S,10.65.

2.2.10 General procedure for the Synthesis of 12 and 13

Equimolecular mixture of *N*-[4-(4-chlorophenyl)-amino -1,3- thiazol – 2 -yl] -2- cyanoacetamide**11** (0.01 mol) and the selected aldehydes such as benzaldehyde and salicylaldehyde (0.01 mol) in 1,4-dioxane (20 mL) containing piperidine (0.5 mL) was heated under reflux for 6h. The reaction mixture was left to cool then poured onto ice / water containing few drops of hydrochloric acid and the formed solid product was collected by filtration and recrystallized from the appropriate solvent.

2.2.10.1 N-[4-(4-Chlorophenyl)amino-1,3-thiazol-2-yl]-2-cyano-3-phenylacrylamide 12

Yield: 60%. m.p.:170 - 172°C. IR (KBr): *u/cm*⁻¹: 3170, 3124 (2 NH), 3047 , 2924 , 2877 (CH) , 2222(CN), 1693 (C=O) .¹H-NMR (DMSO-*d*₆) δ ppm : 6.94 (s ,1H ,C₅-H thiazole) , 7.29 – 7.71 (m, 10 H, Ar-H and C=CH), 11.24 (s, 1H, NH, exchanged by D₂O),11.78 (s,1H, NH exchanged by D₂O).Anal.Calcd. for C₁₉H₁₃Cl N₄ OS(380.85): C, 59.92 ; H , 3.44 ; Cl, 9.31; N, 14.71; S, 8.42. Found: C, 59.62; H , 3.24; Cl, 9.01; N ,14.51; S, 8.22.

2.2.10.2 N-[4-(4-Chlorophenyl)amino-1,3-thiazol-2-yl]-2-imino-2H-chromene-3-carboxamide 13

Yield: 75 % .m.p.: 308 - 310°C. IR (KBr): *u/cm*⁻¹: 3209, 3190, 3170 (3NH) , 3051,2962 (CH) ,1689

(C=O). ¹H-NMR (DMSO-d₆) δ ppm: 6.83 (s, 1H, C₅-H thiazole), 7.02 -7.59 (m, 9 H, Ar-H and C₄-H, coumarin), 10.05 (s, 1H, NH exchanged by D₂O), 11.01 (s, 1H, NH exchanged by D₂O), 12.27 (s, 1H, NH exchanged by D₂O). ¹³C NMR (DMSO-d₆) δ ppm: 116.61, 120.06, 120.69, 120.52, 123.61, 125.35, 128.41, 129.28, 129.53, 129.83, 132.11, 157.34 (C-N), 157.57 (C-O), 162.74 (C=O), 180 (C-S). Anal. Calcd. for C₁₉H₁₃Cl N₄O₂S (396.85): C, 57.50; H, 3.30; Cl, 8.93; N, 14.12; S, 8.08. Found: C, 57.30; H, 3.20; Cl, 8.63; N, 14.02; S, 8.00.

2.2.11 General procedure for the synthesis of compounds 15 and 16

To a cold suspension of powdered potassium hydroxide (0.01 mol) in DMF (20 mL) was added compound **1** (0.01 mol) and phenyl isothiocyanate (0.01 mol). The reaction mixture was stirred at room temperature for 6h, and then treated with ethyl chloroacetate and/or 2-chloro-N-(4-chlorophenyl)acetamide (0.01 mol) and the stirring was continued at room temperature for further 10h. The reaction mixture was poured into 50 mL of cold water. The result solid products were collected by filtration and recrystallized from a mixture of ethanol / DMF (1:1) to give compounds **15** and **16**.

2.2.11.1 Ethyl {N'-[4-(4-chlorophenyl)amino-1,3-thiazol-2-yl]-N-phenyl-carbamimidoyl}thio} acetate 15

Yield: 60%. m.p.: 166-168°C. IR (KBr): u/cm⁻¹: 3283, 3201 (2 NH), 1670 (C=O). ¹H-NMR (DMSO-d₆) δ ppm: 1.02 (t, 3 H, CH₂CH₃), 4.06 (q, 2H, CH₂CH₃), 4.25 (s, 2H, CH₂), 6.81 (s, 1H, C₅-H thiazole), 6.98 - 7.70 (m, 9H, Ar-H), 11.23 (s, 1H, NH exchanged by D₂O), 11.74 (s, 1H, NH exchanged by D₂O). ¹³C NMR (DMSO-d₆) δ ppm: 19 (CH₃), 33.29 (CH₂), 110, 120.67, 121.09, 122.20, 123.51, 124.07, 124.63, 125.10, 128.91, 129.43, 129.69, 135.73, 148.61, 156.35 (C-N), 172.08 (C=O), 182 (C-S). Anal. Calcd. for C₂₀H₁₉Cl N₄O₂S₂ (446.97): C, 53.74; H, 4.28; Cl, 7.93; N, 12.53; S, 14.35. Found: C, 53.54; H, 4.08; Cl, 7.63; N, 12.33; S, 14.15.

2.2.11.2 2-[(4-Chlorophenyl)amino]-2-oxoethyl N'-(4-(4-chlorophenyl)amino-1,3-thiazol-2-yl)-N-phenyl-imidothiocarbamate 16

Yield: 60%. m.p.: 125-126°C. IR (KBr): u/cm⁻¹: 3275, 3190, 3116 (3 NH), 3055, 2978, 2923, 2839 (CH), 1670 (C=O). ¹H-NMR (DMSO-d₆) δ ppm: 4.52 (s, 2H, CH₂), 6.84 (s, 1H, C₅-H thiazole), 6.59-7.64 (m, 13H, Ar-H), 10.24 (s, 1H, NH

exchanged by D₂O), 10.36 (s, 1H, NH exchanged by D₂O), 10.39 (s, 1H, NH exchanged by D₂O). ¹³C NMR (DMSO-d₆) δ ppm: 33.18 (CH₂), 121.14, 123.22, 124.02, 127.38, 127.50, 128.70, 128.87, 128.91, 129.08, 129.48, 129.75, 130.24, 130.81, 137.97, 138.01, 138.33, 138.88, 140.72, 147.02, 156.27 (C-N), 164.83 (C=O), 184, 187 (2 C-S). Anal. Calcd. for C₂₄H₁₉Cl₂N₅O₂S₂ (528.47): C, 54.54; H, 3.62; Cl, 13.42; N, 13.25; S, 12.13. Found: C, 54.24; H, 3.42; Cl, 13.22; N, 13.05; S, 12.03.

2.2.12 General Procedure for the Synthesis of 19 and 20

A mixture of compound **1** (0.01 mol) and 1,3-diphenyl-1H-pyrazole-4-carboxaldehyde **17** or 2-(4-bromophenyl)-1H-indole-3-carboxaldehyde **18** (0.01 mol) was refluxed in ethanol (30 mL) for 15h. The reaction mixture was cooled and poured into crushed ice and filtered. The product obtained was recrystallization from ethanol/ DMF (1:3) to obtain schiff bases **19** and **20**.

2.2.12.1 N⁴-(4-Chlorophenyl)-N²-(1,3-diphenyl-1H-pyrazol-4-yl)methylene)-1,3-thiazole-2,4-diamine 19

Yield: 75%. m.p.: 302 - 304 °C. IR (KBr): u/cm⁻¹: 3124 (NH), 3005, 2993, 2812 (CH). ¹H-NMR (DMSO-d₆) δ ppm: 7.04 (s, 1H, C₅-H thiazole), 7.36 -7.98 (m, 15 H, Ar-H and C₅-H pyrazole), 8.85 (s, 1H, N=CH), 12.15 (s, 1H, NH exchanged by D₂O). ¹³C NMR (DMSO-d₆) δ ppm: 119.70, 119.93, 122.59, 128.19, 129.01, 129.14, 129.38, 129.64, 129.89, 130, 130.17, 135.27, 152.01 (C-N), 185.09 (C-S). Anal. Calcd. for C₂₅H₁₈ClN₅S (455.96): C, 65.85; H, 3.98; Cl, 7.78; N, 15.36; S, 7.03. Found: C, 65.65; H, 3.68; Cl, 7.58; N, 15.16; S, 7.00.

2.2.12.2 N²-(2-(4-Bromophenyl)-1H-indol-3-yl)methylene)-N⁴-(4-chlorophenyl)-1,3-thiazole-2,4-diamine 20

Yield: 75%. m.p.: 280-282°C. IR (KBr): u/cm⁻¹: 3208, 3167 (2 NH), 3020, 2974, 2904, 2866 (CH). ¹H-NMR (DMSO-d₆) δ ppm: 7.11 - 7.30 (m, 9 H, Ar-H and C₅-H thiazole), 7.50 (d, 1H, indole), 7.70 - 7.80 (m, 2H, indole), 8.18 (d, 1H, indole), 9.94 (s, 1H, N=CH), 11.01 (s, 1H, NH, exchanged by D₂O), 12.42 (s, 1H, NH exchanged by D₂O). ¹³C NMR (DMSO-d₆) δ ppm: 112.52, 114.09, 121.51, 122.51, 122.99, 123.95; 124.33, 126.20, 129.43, 132.24, 132.38, 136.37, 147.90 (C-N), 185.48 (C-S). Anal. Calcd. for C₂₄H₁₆BrClN₄S (507.83): C, 56.76; H, 3.18; Br,

15.73 ; Cl, 6.98 ; N, 11.03; S, 6.31. Found : C, 56.56 ; H, 3.08 ; Br, 15.63 ; Cl, 6.68 ; N, 11.00 ; S, 6.01.

2.3 In vitro Antitumor Screening

In vitro anti-tumor activity of newly synthesized compounds **3**, **4**, **6**, **7**, **9**, **10**, **11**, **13**, **15**, **16** and **19** were evaluated against human breast cancer cell line (MCF-7). Breast cancer cell line (MCF-7) was obtained from the American type Cultures Collection (ATCC, Rockville, MD) were kindly provided by Regional Center for Mycology and Biotechnology, Al-Azhar University, Cairo, Egypt. Cell viability was determined by the crystal violet assay [23].

They grow as monolayer and routinely maintained in RPMI-1640 medium supplemented with 10 % inactivated fetal calf serum (FBS) and 50 µg/mL gentamycin at 37°C in a humidified atmosphere containing 5%CO₂. Three hours after seeding, vehicle or cannabinoids at different concentrations were added to the medium and then daily with each change of medium for 4 days. After the treatment, cells were fixed by 4 % paraformaldehyde solution in FBS. Then crystal violet solution (0.5 % crystal violet in 20 % methanol / water) was added. The excess crystal violet solution was washed away with distilled water and the remaining crystals were dissolved in Sorenson's buffer (0.1 M sodium citrate in 50% ethanol/water pH 4.2). Viability was determined by absorbance at 540 nm wavelength using Spectra Max M5 microplate reader.

Number of viable cells was determined using ELISA reader as previously mentioned before and the percentage of viability was calculated as:

$$[1 - (OD_t / OD_c)] \times 100 \%$$

Where OD_t is mean optical density of well treated with the test sample, OD_c is mean optical density of untreated cell. IC₅₀ values the concentration required to cause toxic effects in 50% if intact cells was estimated from graphic plots. Experiments were carried out in triplicate, and results are reported in Table 1.


3. RESULTS AND DISCUSSION

3.1 Chemistry


The synthesis of the new compounds is outlined in Schemes 1- 4. The key starting compound *N*^t-(4-chlorophenyl)-1,3-thiazole-2,4-diamine **1** was prepared by heating a mixture of equimolar amounts of the 2-chloro-*N*-(4-chlorophenyl)-acetamide and thiourea according to the reported method [22]. Reaction *N*^t-(4-chlorophenyl)-1,3-thiazole-2,4-diamine **1** with ammonium thiocyanate in the presence of HCl [24] afforded *N*-[1,3-thiazol-2-yl]thiourea derivative **2** (Scheme 1). The structure of **2** was supported on the basis of elemental analyses and spectral data. The ¹H-NMR spectrum (DMSO-d₆) of compound **2** showed a D₂O-exchangeable single signals at δ 4.27 ppm, δ 10.12 ppm and δ 10.50 ppm assigned to NH₂ and two NH protons respectively. Its mass spectrum showed a molecular ion peak at *m/z* 485 corresponding to a molecular formula C₁₀H₉ClN₄S₂.

The reaction of *N*^t-(4-chlorophenyl)-1,3-thiazole-2,4-diamine **1** with phenyl isothiocyanate in 1,4-dioxane in the presence of TEA [25] to give the *N*-[1,3-thiazol-2-yl]-*N*-phenylthiourea derivative **3** (Scheme 1). The IR spectrum displayed absorption bands at 3217 cm⁻¹, 3186 cm⁻¹, 3116 cm⁻¹ and 1250 cm⁻¹ due to 3 NH and C=S groups respectively. The ¹H-NMR spectrum (DMSO-d₆) showed a D₂O-exchangeable three signals at δ 10.02 ppm, δ 11.03 ppm and δ 11.54 ppm assigned to three NH protons. The mass spectrum showed a molecular ion peak at *m/z* 361 corresponding to a molecular formula C₁₆H₁₃ClN₄S₂. Further structure elucidation of compound **3** was obtained through the study of its reactivity towards chemical reagents. Thus, the reaction of **3** with ethyl cyanoacetate and anisaldehyde in the presence of TEA as catalysis [26] to give 4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carbonitrile **4**. A plausible mechanism for the formation **4** which the intermediate **A** and **B** are obtained first, then intramolecular cyclization to give **4** (Scheme 2). The IR spectrum of **4** displayed absorption bands at 3275 cm⁻¹ (NH), 2214 cm⁻¹ (CN), 1670 cm⁻¹ (C=O) and 1246 cm⁻¹ (C=S). The ¹H-NMR spectrum (DMSO-d₆) showed a D₂O-exchangeable signal at δ 8.27 ppm assigned to NH proton and signal at δ 3.25 ppm for OCH₃ proton. ¹³C NMR spectrum showed signal at δ 62.52 ppm (OCH₃), δ 116.63 ppm (CN), δ 162.81 ppm (C=O) and δ 186 ppm (C=S). The reaction of thiourea derivatives **3** with 1-(4-aminophenyl)-3-(4-chlorophenyl)prop-2-en-1-one **5** in the presence of sodium hydroxide to give pyrimidine-2(1*H*)-thione derivative **6**. The IR spectrum displayed absorption bands at 3217 cm⁻¹, 3166 cm⁻¹, 3116 cm⁻¹, 1254 cm⁻¹ to NH₂, NH and C=S groups respectively. The ¹H-NMR spectrum

(DMSO- d_6) showed a D₂O-exchangeable signals at δ 5.02 ppm, δ 8.91 ppm assigned to NH₂ and NH protons and the signal at δ 4.48 ppm, δ 6.60 ppm assigned to C₄-H and C₅-H pyrimidine.




Scheme 1. Synthesis of compounds 1-6



R = 4-Cl C₆H₄NH, R₁ = 4-OCH₃C₆H₄

Scheme 2. Proposed mechanism of formation of compound 4



Scheme 3. Synthesis of compounds 7-10

Diacylation of thiazole derivative **1** using acetic anhydride under reflux condition [27] gave *N*-acetyl-*N*-(1,3-thiazol-2-yl) acetamide derivative **7** (Scheme 3). The structure of compound **7** was established based on both elemental analysis and spectral data. The $^1\text{H-NMR}$ showed singlet signals at δ 2.70 ppm, δ 2.86 ppm for acetyl protons. $^{13}\text{C NMR}$ spectrum showed the signal at δ 168.42 ppm, δ 170.44 ppm to (2 C=O).

Condensation of thiazole derivative **1** with phenacyl bromide and/or 2-chloro-*N*-(4-chlorophenyl)acetamide in the presence of catalytic amount of TEA in ethanol [28] afforded 2-(1,3-thiazol-2-ylamino)-1-phenylethanone derivative **8** and/or 2-(1,3-thiazol-2-ylamino)-*N*-(4-chlorophenyl)acetamide **9**. The structure of the compound **8** and **9** were based on their elemental analysis and spectral data. $^1\text{H NMR}$ spectrum of **8** exhibited a singlet signal at δ 4.21 ppm due to CH_2 . The mass spectrum of **8** displayed the molecular ion peak at m/z 344 corresponding to the molecular formula $\text{C}_{17}\text{H}_{14}\text{Cl N}_3\text{OS}$. Cyclocondensation of 2-(1,3-thiazol-2-ylamino)-*N*-(4-chlorophenyl)acetamide **9** with ammonium thiocyanate in glacial acetic acid [29] afforded 1-(1,3-thiazol-2-yl)-1*H*-imidazole-2(3*H*)-thione derivative **10** (Scheme 3). The $^1\text{H NMR}$ spectrum (DMSO-d_6) of **10** showed a D_2O -exchangeable signal at δ 8.61 ppm, δ 10.02 ppm

and δ 11.21 ppm assigned to the 3 NH protons. In addition $^{13}\text{C NMR}$ spectrum showed the signal at δ 186 to C=S.

Reaction, of *N*-(4-chlorophenyl)-1,3-thiazole-2,4-diamine **1** with mixture of acetic anhydride and cyanoacetic acid [30] to yield the corresponding *N*-(1,3-thiazol-2-yl)-2-cyanoacetamide derivative **11** (Scheme 4). The structure of **11** has been assigned as a reaction product on the basis of analytical and spectral data. The IR spectrum displayed absorption bands at 3136 cm^{-1} , 3100 cm^{-1} and 2200 cm^{-1} due to 2 NH and CN groups respectively. The mass spectrum showed a molecular ion peak at m/z 293 corresponding to a molecular formula $\text{C}_{12}\text{H}_9\text{Cl N}_4\text{OS}$.

The reaction of cyanoacetamide derivatives **11** with benzaldehyde [31] gave the benzalidine derivative **12**, while its reaction with salicylaldehyde [32] produced the coumarin derivative **13**. The plausible mechanism for the formation of compound **13** may be attributed to the initial, through the formation of the aryldine derivative **C** followed by intramolecular cyclization to give **13**. The structure of compounds **12** and **13** were as signed on the basis of the elemental analysis and spectral data. The IR spectrum of compound **13** revealed the absence of CN absorption band and the presence of new absorption bands at

3209 cm^{-1} , 3190 cm^{-1} , 3170 cm^{-1} assignable to 3 NH groups and band at 1689 cm^{-1} due to C=O group. ^{13}C NMR data showed signals at δ 162.74 ppm to C=O.


Reaction of N^4 -(4-chlorophenyl)-1,3-thiazole-2,4-diamine **1** with phenyl isothiocyanate in dry DMF at room temperature yielded the non-isolable intermediate **14** and then reaction with α -halo-carbonyl compounds [33] such as ethyl chloroacetate and / or 2-chloro- N -(4-chlorophenyl)acetamide afforded ethyl $\{N$ -[1,3-thiazol-2-yl]- N -phenyl-carbamimidoylthio} acetate **15** and 2-[(4-chlorophenyl) amino] -2-oxoethyl N -(1,3-thiazol-2-yl)- N -phenyl-imidothiocarbamate **16** (Scheme 5). The structures of compounds **15** and **16** were established and confirmed by their elemental analysis and spectral data. For example IR spectrum of **15** showed absorption bands at 3283 cm^{-1} , 3201 cm^{-1} and 1670 cm^{-1} corresponding to 2 NH and C=O groups respectively. The $^1\text{H-NMR}$ spectrum of **15** showed a triplet at δ 1.02 ppm, a quartet at δ 4.06 ppm correspond to CH_2CH_3 group and singlet at δ 4.25 ppm correspond to CH_2 protons. In addition, ^{13}C NMR data showed signals at δ 19

ppm, δ 33.29 ppm, δ 172.08 ppm to CH_3 , CH_2 and C=O respectively.


Moreover, the reaction of compounds **1** with 1,3-diphenyl-1 H -pyrazole-4-carboxaldehyde **17** or 2-(4-bromophenyl)-1 H -indole-3-carboxaldehyde **18** [34,35] afforded N^2 -(substituted methylene)- N^4 -(4-chlorophenyl)-1,3-thiazol-2,4-diamine **19** and **20** respectively (Scheme 5). The structures of **19** and **20** were elucidated by microanalysis and spectral data. For example IR spectrum of **20** showed absorption bands at 3208 cm^{-1} , 3167 cm^{-1} corresponding to 2 NH groups. The $^1\text{H-NMR}$ spectrum of **20** showed a single signal at δ 9.94 ppm corresponds to N=CH proton.

3.2 In Vitro Anti-Tumor Activity

The *in vitro* anticancer activity of the newly synthesized compounds **3**, **4**, **6**, **7**, **9**, **10**, **11**, **13**, **15**, **16** and **19** are evaluated against human breast cancer cell line (MCF-7) and cell viability was determined by the crystal violet assay. Cisplatin used as a reference drug. The results are presented in (Table 1; Figs. 1 and 2).



Scheme 4. Synthesis of compounds **11** – **13**



Scheme 5. Synthesis of compounds 14-20




Fig. 1. Cell viability % of human breast cancer MCF- 7 with different concentrations of the tested compounds

The results indicated that compounds 6, 9 and 16 showed the highest inhibitory effect against breast cancer cell line (MCF-7) than control drug cisplatin. Compounds 3, 7, 10 and 11 showed moderated growth inhibitory effect and compounds 4, 13, 15 and 19 showed very low


activity towards human breast cancer cell line (MCF-7).

Comparing compound 6 with 9 and 16, it is obvious that the presence of the pyrimidine ring at position 2 of thiazole ring, in compound 6

Table 1. *In vitro* anticancer activities of synthesis compounds against human breast cancer MCF- 7 cell line

Compd No.	Compound concentration ($\mu\text{g/ml}$)						
	1.56 ($\mu\text{g/ml}$)	3.12 ($\mu\text{g/ml}$)	6.25 ($\mu\text{g/ml}$)	12.5 ($\mu\text{g/ml}$)	25 ($\mu\text{g/ml}$)	50 ($\mu\text{g/ml}$)	IC ₅₀ ($\mu\text{g/ml}$)
	Cell viability %						
3	98.12 \pm 0.19	91.75 \pm 0.12	84.52 \pm 0.34	69.78 \pm 1.44	31.63 \pm 0.33	24.17 \pm 0.21	19 \pm 0.43
4	100 \pm 0.12	100 \pm 0.14	99.63 \pm 0.02	97.28 \pm 0.12	91.13 \pm 0.08	82.85 \pm 0.14	170 \pm 3.8
6	57.09 \pm 1023	45.93 \pm 0.39	37.18 \pm 0.2	28.06 \pm 0.04	22.37 \pm 0.08	18.29 \pm 0.23	2.55 \pm 0.07
7	99.71 \pm 0.07	96.18 \pm 0.14	89.04 \pm 0.25	78.93 \pm 0.13	60.22 \pm 1.46	39.35 \pm 0.17	37.2 \pm 0.8
9	65.13 \pm 1.73	48.65 \pm 0.54	32.94 \pm 0.32	24.13 \pm 0.09	18.26 \pm 0.08	14.31 \pm 0.15	2.99 \pm 0.17
10	100	99.61 \pm 0.04	92.73 \pm 0.15	84.68 \pm 0.24	72.95 \pm 1.71	34.26 \pm 0.44	39.8 \pm 0.6
11	98.24 \pm 0.12	92.31 \pm 0.25	86.95 \pm 0.21	71.66 \pm 1.94	45.91 \pm 0.75	34.06 \pm 0.42	23 \pm 0.8
13	100	100	100	100	100	98.76 \pm 0.02	>400
15	98.72 \pm 0.08	96.04 \pm 0.21	89.72 \pm 0.44	80.63 \pm 0.39	69.18 \pm 1.24	43.84 \pm 0.98	43.9 \pm 1.3
16	69.41 \pm 0.31	56.29 \pm 0.39	48.12 \pm 0.32	37.54 \pm 0.75	28.04 \pm 0.42	20.87 \pm 0.26	5.53 \pm 0.25
19	100	98.12 \pm 0.08	91.45 \pm 0.23	80.75 \pm 0.16	63.82 \pm 0.24	50.67 \pm 1.25	52.5 \pm 1.3
Cisplatin	70.88 \pm 0.16	61.74 \pm 0.36	52.85 \pm 0.98	46.71 \pm 1.37	34.62 \pm 0.89	23.79 \pm 0.41	5.71 \pm 0.21

IC₅₀ value: corresponds to the concentration required required to cause toxic effects in 50% if intact

**Fig. 2. Evaluation of IC₅₀ of test compounds**

resulted in a higher inhibitory effect than **9** which has a N- (4- chlorophenyl) acetamide group at position **2** of thiazole ring and **16** which has a 2-[(4-chlorophenyl) amino]-2-oxoethyl N-phenyl-imidothiocarbamate group at position **2** of thiazole ring. The antiproliferative activity of the test compounds against tumor cell to measure by IC₅₀ $\mu\text{g} / \text{mL}$ which is concentration require causing toxic effects in 50% if intact.

4. CONCLUSION

In this work, variety of heterocyclic systems have been synthesized from N⁴-(4-chlorophenyl)-1,3-thiazole-2,4-diamine. The new synthesis compounds **3**, **4**, **6**, **7**, **9**, **10**, **11**, **13**, **15**, **16** and **19** have been evaluated for the *in vitro* anti-tumor activity against human breast cancer cell line (MCF-7) and cell viability was determined by the

crystal violet assay ,cisplatin used as a reference drug. Compounds **6**, **9** and **16** showed best cytotoxic activity against cancer cell higher than that of cisplatin .Hence it can be suggested that **6**, **9** and **16** could be used as leads in the design and development of new anticancer drugs.

COMPETING INTERESTS

Author has declared that no competing interests exist.

REFERENCES

1. Nussbaumer S, Bonnabry P, Veuthey J. Fleury Souverain S Analysis of anticancer drugs: A review. Talanta. 2011;85:2265-2289.

2. Albrecht T, Mckee M, Alexe DM, Coleman MP, Martin-Moreno JM. Making progress against cancer in Europe in 2008. *European Journal of Cancer*. 2008; 44:1451-1456.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics. *A Cancer Journal for Clinicians*, 2006; 56:106-130.
4. Bhuran HA, Kini SJ. Synthesis, anticancer activity and docking of some substituted benzothiazoles as tyrosine kinase inhibitors. *Journal of Molecular Graphics and Modelling*. 2010;29:32-37.
5. Martins P, Jesus J, Santos S, Raposo L, Roma-Rodrigues C, Baptista PV, Fernandes AR. Heterocyclic anticancer compounds: Recent advances and the paradigm shift towards the use of nanomedicine's Tool Box. *Molecules*. 2015;20:16852-16891.
6. Campos J, Nunez C, Diaz JJ, Sanchez RM, Gallo MA, Espinosa A. Anticancer bisquaternary heterocyclic compounds: A Ras-ional design. *II Farmaco*. 2003;58:221-229.
7. Annadurai S, Martinez R, Canney DJ, Eidem T, Dunman PM, Abou-Gharbia M. Design and synthesis of 2-aminothiazole based antimicrobials targeting MRSA. *Bioorganic & Medicinal Chemistry Letters*. 2012;2(24):7719-7725.
8. Stankova I, Chuchkov K, Shishkov S, Kostova K, Mukova L, Galabov AS. Synthesis, antioxidative and antiviral activity of hydroxycinnamic acid amides of thiazole containing amino acid. *Amino Acide*. 2009; 37(2):383-388.
9. Fatima A, Kulkarni R, Mantipragada B. Design and synthesis of N-substituted aminothiazole compounds as anti-inflammatory. *Der Pharma Chemica*. 2015; 7(3):212-220.
10. Zhou A, Wu H, Pan J, Wang X, Li J, Wu Z, Hui A. Synthesis and evaluation of paeonol derivatives as potential multifunctional agents for the treatment of alzheimer's disease. *Molecules*. 2015;20:1304-1318.
11. Karuvalam RP, Haridas KR, Nayak SK, Guru Row TN, Rajeesh P, Rishikesan R, Suchetha Kumari N. Design, synthesis of some new (2-aminothiazol-4-yl)methyl ester derivatives as possible antimicrobial and antitubercular agents. *European Journal of Medicinal Chemistry*. 2012;49:172-182.
12. Amin KM, Rahman DE, Al-Eryani YA. Synthesis and preliminary evaluation of some substituted coumarins as anti-convulsant agents. *Bioorganic & Medicinal Chemistry*. 2008;16(10):5377-5388.
13. Rawal RK, Tripathi R, Katti SB, Pannecouque and De Clercq E. Design, synthesis, and evaluation of 2-aryl-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents. *Bioorganic & Medicinal Chemistry*, 2007;15(4):1725-1731.
14. Hamamichi N, Natrajan A, Hecht S. On the role of individual bleomycin thiazoles in oxygen activation and DNA cleavage. *J. Am. Chem. Soc.* 1992;114(16):6278-6291.
15. Sinha SC, Sun J, Wartmann M, Lemer RA. Synthesis of epothilone analogues by antibody-catalyzed resolution of thiazole aldol synthons on a multigram scale. Biological consequences of C-13 alkylation of epothilones. *Chembiochem*. 2001;2(9): 656-665.
16. Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, Shen Z, Cook LS, Doweiko AM, Pitt S, Pang S, Shen DR, et al. 2-Aminothiazole as a novel kinase inhibitor template structure activity relationship studies toward the discovery of *N*-(2-chloro-6-methylphenyl)-2-[*N*-(4-(2-hydroxyethyl)-1-piperazinyl)-*N*-(2-methyl-4-pyrimidinyl)amino]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. *Journal of Medicinal Chemistry*. 2006;49(23):6819-6832.
17. Veach DR, Namavari M, Pillarsetty N, Santos EB, Beresten-Kochetkov T, Caryl Lambek C, et al. Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib. *Journal of Medicinal Chemistry*. 2007;50(23):5853-5857.
18. Chen B, Zhao R, Bei Wang B, Droghini R, Lajeunesse J, Sirard P, Endo M, Balasubramanian B, Barrish JC. New and efficient preparation of 2-aminothiazole-5-carbamides: Applications to the synthesis of the anti-cancer drug dasatinib. *ARKIVOC*. 2010;(vi):32-38.
19. Aliabadi A, Shamsa F, Ostad SN, Emami S, Shafiee A, Davoodi J, et al. Synthesis and biological evaluation of 2-phenylthiazole-4-carboxamide derivatives as anticancer agents. *European Journal of Medicinal Chemistry*. 2010;11:5384-5389.
20. Nazari Tarhan H, Hosseinzadeh L, Aliabadi A, Babak G, Foroumadi A. Cytotoxic and apoptogenic properties of 2-

- phenyl thiazole-4-carboxamide derivatives in human carcinoma cell lines. *Journal of Reports in Pharmaceutical Sciences*. 2012;1:1-7.
21. Aliabadi A, Foroumadi A, Safavi M, Kaboudian Ardestani S. Synthesis, molecular docking and cytotoxicity evaluation of 2-(4-substitutedbenzyl) isoindoline-1,3-dione derivatives as anti-cancer agents. *Journal of Reports in Pharmaceutical Sciences*. 2012;1:19-22.
 22. Kumar BC, Reddy KR, Fasiulla Shridhara AM. Synthesis, characterization and antimicrobial activity of some novel 2, 3-disubstituted thiazolidin-4-one derivatives. *Journal of Chemical and Pharmaceutical Research*. 2013;5(6):1-6.
 23. Hongo T, Mizuno Y, Haraguchi S, Yoshida TO. A new anticancer drug sensitivity test using the microplate culture and surviving tumor cell staining method. *Gan to Kagaku Ryoho*. 1986;13(2):247-254.
 24. Gangadhar SP, Ramesh DK, Mahajan SK. Synthesis, characterization and anti-convulsant activity of 3-substituted 2-thiohydantoin derivatives. *International Journal of Research In Pharmacy and Chemistry*. 2013;3(4):793-796.
 25. Mohareb RF, Al-farouk FO. Anti-tumor and anti-leishmanial evaluations of novel thiophene derivatives derived from the reaction of cyclopentanone with elemental sulphur and cyano-methylene reagents. *Organic Chemistry Current Research*. 2012;1(1):1-6.
 26. Farag AM, Kheder NA, Dawood KM. A convenient access to functionalized 1,3,4-thiadiazole,thiazole,thiophene, thieno [2,3-d]pyrimidine, pyrimidine, and thiazolo [3,2-a]pyrimidine derivatives. *American Journal of Organic Chemistry*. 2015;5(2):73-77.
 27. Al-Bayati RI, Ahamad MR, Ahamed LS. Synthesis and biological activity investigation of some quinoline-2-one derivatives. *American Journal of Organic Chemistry*. 2015;5(4):125-135.
 28. Soliman EA, Samir A, Hassan AM, Mohy-Eldin MS, Abd El-Naim G. Synthesis of pyrroles and condensed pyrroles as anti-inflammatory agents with multiple activities and their molecular docking study. *Open Journal of Synthesis Theory and Applications*. 2014;3:27-36.
 29. Guravaiah N, Rao VR. Efficient, stereoselective approach to the synthesis of 3-(1-phenyl-2-(zstyrylsulfonyl)-1H-imidazol-4-yl)-2H-chromen-2-ones. *Synthetic Communication*. 2011;41:1167-1174.
 30. Ibrahim HM, Behbehani H, Makhseed S, Elnagdi MH. Acylation of hetero-aromatic amines: Facile and efficient synthesis of a new class of 1,2,3-triazolo [4,5-b] pyridine and pyrazolo [4,3-b] pyridine derivatives. *Molecules*. 2011;16:3723-3739.
 31. Mohareb RM, Fleita DH, Sakka OK. Novel synthesis of hydrazide- hydrazone derivatives and their utilization in the synthesis of coumarin, pyridine, thiazole and thiophene derivatives with antitumor activity. *Molecules*. 2011;16:16-27.
 32. Khalil M, Berghot MA, MA Gouda MA. Synthesis and antibacterial activity of some new heterocycles incorporating phtha-lazine. *European Journal of Medicinal Chemistry*. 2009;44(11):4448-4454.
 33. Fadda AA, Khalil AM, Tawfik EH. Enaminonitriles in heterocyclic synthesis: Synthesis and biological evaluation of novel indeno [2,1-b] thiophene derivatives. *Turkish Journal of Chemistry*. 2013; 37:134-148.
 34. Fadda AA, Abdel-Rahman AH, Hamed EA, Khalil EH. Utility of enaminonitriles in heterocyclic synthesis: Synthesis and antimicrobial activity of some new azole and azine derivatives. *American Journal of Organic Chemistry*. 2012;2(2):7-13.
 35. Esther Rani V, Ravindranath LK. Synthesis and antimicrobial activity of novel pyrazole-5-one containing 1,3,4-oxadiazole sulfonyl phosphonates. *American Journal of Organic Chemistry*. 2016;6(1):1-7.

© 2016 Salman; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
<http://sciencedomain.org/review-history/15351>